# SECRETED PHOSPHOPROTEINS ASSOCIATED WITH TUMORIGENICITY

> **NIH NIH R01** · BETH ISRAEL DEACONESS MEDICAL CENTER · 1988 · $132,191

## Abstract

A wide variety of neoplastically transformed rodent and human fibroblast
and epithelial cells secrete a transformation-dependent phosphoprotein with
a molecular weight of approximately 62,000.  Tumorigenic cells exhibit a
10-fold or greater increase in secretion of this phosphoprotein as compared
to their normal or nontumorigenic counterparts and this increase is
independent of the transforming agent.  Cancer patients with carcinomas of
the liver, pancreas, colon, breast, prostate, ovary, or lung have all been
shown to have markedly elevated plasma levels of what is almost certainly
this same protein.

A major goal of the proposed research is to determine the biological
function of this phosphoprotein and relate this function to the biology of
tumor growth.  In particular, the phosphoprotein, which is closely relate
to an as of yet unidentified normal plasma protein, will be subjected to
sequence analysis in order to assess its potential relatedness to any of
the previously sequenced proteins.  Sequence information will be used to
guide efforts to identify biological or enzymatic activity associated with
the phosphoprotein.  In addition, studies will be performed to further
characterize the apparently specific interaction of the phosphoprotein with
the surfaces of various cell types.

Another major goal of the project is to further assess the possibility that
the phosphoprotein is a useful marker for monitoring tumor progression or
reacurrence, and effectiveness of therapy.  In order to make this
assessment, significant numbers of serum samples from patients with a
variety of neoplastic and non-neoplastic conditions will be analyzed.  In
addition, patients with malignancies will be followed during the course of
therapy to determine if phosphoprotein blood levels correlate with apparent
tumor burden.

## Key facts

- **NIH application ID:** 3171753
- **Project number:** 5R01CA034025-06
- **Recipient organization:** BETH ISRAEL DEACONESS MEDICAL CENTER
- **SAM.gov UEI:** C1CPANL3EWK4
- **Principal Investigator:** DONALD R SENGER
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1988
- **Award amount:** $132,191
- **Award type:** 5
- **Project period:** 1983-03-01 → 1989-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3171753

## Citation

> US National Institutes of Health, RePORTER application 3171753, SECRETED PHOSPHOPROTEINS ASSOCIATED WITH TUMORIGENICITY (5R01CA034025-06). Retrieved via MORVS 2026-10-24 from https://api.morvs.ai/grant/nih/3171753. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*